Radio-protective effect of hydrogen rich water combined with amifostine in mice

Abstract

Background: Hydrogen has been demonstrated can selec vely reduce the hydroxyl, which is the main cause of ionizing radia on-induced damage. Amifos ne (AM) is the only radioprotec ve drug approved by the U.S. Food and Drug Administra on for use in radiotherapy. The purpose of the present study was to inves gate the combined radio-protec ve effect of hydrogen rich water (HRW) and AM. Materials and Methods: Male ICR mice were treated intragastrically with HRW or/and intraperitoneally with AM 30 minutes prior to 9.0 Gy whole body irradia on from a 60 Co source (dose rate 0.96Gy/min). Then the survival rate for 30 days, the hematological parameters, the Clinical chemistry parameters and the bone marrow nucleated cells were examined. Results: We found that the mice treated with HRW and AM before irradia on could increase the 30-day survival rate and improve the body weight be2er than the HRW or AM treatment alone group and irradia on alone group. Hematological test and Clinical chemistry assays also showed the same results that HRW combined AM could be2er improve the recovery of hemopoie c system and alleviate the detrimental effects of radia on. Conclusion: The results indicate that the combined applica on of HRW and AM may be a be2er method for radia on therapy.

Highly Catalytic Niobium Carbide (MXene) Promotes Hematopoietic Recovery after Radiation by Free Radical Scavenging

“…Moreover, at the lethal dose (6.5 Gy) of TBI, the 30-day survival rate was 30% in the mice with 5 mg/kg Nb 2 C-PVP pretreatment with the median survival time of 21 days and a 95% CI of 18–25 days, 50% in the mice with 10 mg/kg Nb 2 C-PVP pretreatment with the median survival time of 24 days and a 95% CI of 21–28 days, and 81% in the mice with 20 mg/kg Nb 2 C-PVP pretreatment with the shortest survival time of 21 days as compared to IR alone mice with 100% mortality and a mean survival time of 15 days (95% CI: 14–16 days) (Figure a). For comparison, pretreatment of AM at a dose of 400 mg/kg, the highest efficacy dose, 30 min before TBI provided 90% survival with the shortest survival time of 20 days in mice after TBI of 6.5 Gy, which was similar to mice in the 20 mg/kg Nb 2 C-PVP pretreatment plus 6.5 Gy TBI group (Figure a). Recently, it has been reported that Fe@C, CoNi@C nanoshields, and cysteine-protected MoS 2 nanodots exhibited higher efficiency in radiation protection, which enhanced the surviving fractions of mice exposed to lethal TBI up to 90%, 80%, and 79%, respectively. , Taken together, Nb 2 C-PVP possesses significant radioprotective activity in vivo, which is comparable to that of the standard radioprotectant AM and several potent nanoradioprotectors, and a dose of 20 mg/kg Nb 2 C-PVP is recommended.…”